A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis
Clinical trial NCT06921759 · COMPLETED
Trial details
- NCT number
- NCT06921759
- Sponsor
- Eli Lilly and Company
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-04-21
- Primary completion
- 2026-05-13
- Enrollment
- 221
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.